PMID- 36215830
OWN - NLM
STAT- MEDLINE
DCOM- 20221107
LR  - 20221213
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 136
DP  - 2022 Nov
TI  - Effectiveness and safety of perampanel as adjunctive therapy among Chinese 
      patients with focal-onset epilepsy: A real-world prospective observational study.
PG  - 108937
LID - S1525-5050(22)00386-9 [pii]
LID - 10.1016/j.yebeh.2022.108937 [doi]
AB  - OBJECTIVE: Perampanel (PER) has previously been shown to be effective and 
      tolerable when used as an adjunctive therapy for patients with focal-onset 
      seizures (FOS). This study aimed to evaluate the effect of PER as adjunctive 
      therapy for patients with FOS in the Chinese population under real-world 
      conditions for 1 year. METHODS: A prospective, single-center, 1-year 
      observational study was conducted at Huashan Hospital, enrolling both under age 
      (>/=4 years old) and adult patients with FOS. Response to PER was assessed at 3-, 
      6-, and 12-month checkpoints by analyzing the 50 % responder rate, the 
      seizure-free rate, and reduction in seizure frequency. RESULTS: One hundred and 
      eight patients (mean age: 26.6 years, 56.5 % males) with FOS were included, with 
      seventy-six patients finishing the 1-year follow-up (retention rate: 70.4 %, mean 
      PER dose: 4.3 mg/day). The seizure frequency was reduced significantly at 3, 6, 
      and 12 months relative to baseline (p < 0.001 for each seizure type). At 
      12 months, the responder rate was 65.8 %, and the seizure-free rate was 39.5 %. A 
      significantly higher responder rate was found in patients with focal to bilateral 
      tonic-clonic seizures (p = 0.024), among which the percentage of patients with 
      sleep-related epilepsy was significantly high (p = 0.045). Responders had a lower 
      number of concomitant anti-seizure medications (ASMs) than the non-responders 
      (p = 0.009). Drug-related adverse events (AEs) were reported in 37 % of patients, 
      mostly mild or moderate, and the patients who experienced AEs had a higher daily 
      dose of PER than those who did not (p = 0.026). CONCLUSION: Perampanel, an add-on 
      therapy for focal-onset seizures, was found to be effective and tolerable in 
      Chinese patients at 12 months.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Wang, Qinyue
AU  - Wang Q
AD  - Department of Neurology, Huashan Hospital, Fudan University, China.
FAU - Xu, Ye
AU  - Xu Y
AD  - Department of Neurology, Huashan Hospital, Fudan University, China.
FAU - Chen, Yuncan
AU  - Chen Y
AD  - Department of Neurology, Huashan Hospital, Fudan University, China.
FAU - Wu, Xunyi
AU  - Wu X
AD  - Department of Neurology, Huashan Hospital, Fudan University, China; National 
      Center for Neurological Disorders, Shanghai, China. Electronic address: 
      dr.xunyiwu@163.com.
FAU - Ge, Yan
AU  - Ge Y
AD  - Department of Neurology, Huashan Hospital, Fudan University, China; National 
      Center for Neurological Disorders, Shanghai, China.
FAU - Zhu, Guoxing
AU  - Zhu G
AD  - Department of Neurology, Huashan Hospital, Fudan University, China; National 
      Center for Neurological Disorders, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20221007
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
RN  - H821664NPK (perampanel)
RN  - 0 (Anticonvulsants)
RN  - 0 (Pyridones)
SB  - IM
MH  - Adult
MH  - Male
MH  - Humans
MH  - Child, Preschool
MH  - Female
MH  - Prospective Studies
MH  - *Anticonvulsants/adverse effects
MH  - Treatment Outcome
MH  - *Epilepsies, Partial/drug therapy/chemically induced
MH  - Pyridones/adverse effects
MH  - China/epidemiology
MH  - Drug Therapy, Combination
OTO - NOTNLM
OT  - Add-on therapy
OT  - Efficacy
OT  - Epilepsy
OT  - Focal-onset seizures
OT  - Perampanel
OT  - Tolerability
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/10/11 06:00
MHDA- 2022/11/08 06:00
CRDT- 2022/10/10 18:23
PHST- 2022/06/28 00:00 [received]
PHST- 2022/09/19 00:00 [revised]
PHST- 2022/09/25 00:00 [accepted]
PHST- 2022/10/11 06:00 [pubmed]
PHST- 2022/11/08 06:00 [medline]
PHST- 2022/10/10 18:23 [entrez]
AID - S1525-5050(22)00386-9 [pii]
AID - 10.1016/j.yebeh.2022.108937 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2022 Nov;136:108937. doi: 10.1016/j.yebeh.2022.108937. Epub 2022 
      Oct 7.